The obesity pandemic continues unabated, one can expect to see an increase in the prevalence
of TID/T2D and associated CKD. As a result, death will rise, preceded by an increase in
kidney failure, requiring dialysis and renal transplantation. Innovative medical treatment
may help prevent CKD across our healthcare system. The guideline of the American Diabetes
Association (ADA) and European Association for the Study of Diabetes (EASD) suggest that
patients with obesity, TID/ T2D, and CKD needed either glucagon-like peptide 1 receptor
analogs (GLP1-RA) or sodium-glucose cotransport-2 inhibits (SGLT2i). The clinical trials show
the benefits of these medications in TID/T2D. This study will provide evidence of discrete
metabolic pathways by the GLP1RA/or SGLT2i alone or in combination contributed to metabolic
control.